- World Pharma News Home » Clinical Trials » Crestor Outcomes Study JUPITER Closes Early Due To Unequivocal Evidence Of Benefit
(a free service delivered by FeedBurner)
AstraZeneca today announced it has decided to stop the CRESTOR JUPITER clinical study early based on a recommendation from an Independent Data Monitoring Board and the JUPITER Steering Committee, which met on March 29, 2008. The study will be stopped early because there is unequivocal evidence of a reduction in cardiovascular morbidity and mortality amongst patients who received CRESTOR when compared to placebo.
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Comments